Literature DB >> 22162580

Major response to everolimus in melanoma with acquired imatinib resistance.

Lu Si1, Xiaowei Xu, Yan Kong, Keith T Flaherty, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Siming Li, Jie Dai, Weiwei Yu, Jun Guo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22162580     DOI： 10.1200/JCO.2011.37.9644

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

Review 1.  Mucosal melanoma: pathogenesis, clinical behavior, and management.

Authors:  Michael A Postow; Omid Hamid; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Authors:  Kevin Kalinsky; Sandra Lee; Krista M Rubin; Donald P Lawrence; Anthony J Iafrarte; Darell R Borger; Kim A Margolin; Mario M Leitao; Ahmad A Tarhini; Henry B Koon; Andrew L Pecora; Anthony J Jaslowski; Gary I Cohen; Timothy M Kuzel; Christopher D Lao; John M Kirkwood
Journal:  Cancer       Date:  2017-03-23       Impact factor: 6.860

Review 3.  Melanoma: oncogenic drivers and the immune system.

Authors:  Niki Karachaliou; Sara Pilotto; Cristina Teixidó; Santiago Viteri; María González-Cao; Aldo Riso; Daniela Morales-Espinosa; Miguel Angel Molina; Imane Chaib; Mariacarmela Santarpia; Eduardo Richardet; Emilio Bria; Rafael Rosell
Journal:  Ann Transl Med       Date:  2015-10

4.  Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Authors:  Richard D Carvajal; Donald P Lawrence; Jeffrey S Weber; Thomas F Gajewski; Rene Gonzalez; Jose Lutzky; Steven J O'Day; Omid Hamid; Jedd D Wolchok; Paul B Chapman; Ryan J Sullivan; Jerrold B Teitcher; Nikhil Ramaiya; Anita Giobbie-Hurder; Cristina R Antonescu; Michael C Heinrich; Boris C Bastian; Christopher L Corless; Jonathan A Fletcher; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2015-02-18       Impact factor: 12.531

5.  FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma.

Authors:  Pauline Tétu; Julie Delyon; Jocelyne André; Coralie Reger de Moura; Malak Sabbah; Ghanem E Ghanem; Maxime Battistella; Samia Mourah; Céleste Lebbé; Nicolas Dumaz
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

6.  Genetics of melanoma.

Authors:  Janet Wangari-Talbot; Suzie Chen
Journal:  Front Genet       Date:  2013-01-25       Impact factor: 4.599

7.  Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Authors:  Fleur Weeber; Geert A Cirkel; Marlous Hoogstraat; Sander Bins; Christa G M Gadellaa-van Hooijdonk; Salo Ooft; Erik van Werkhoven; Stefan M Willems; Marijn van Stralen; Wouter B Veldhuis; Nicolle J M Besselink; Hugo M Horlings; Neeltje Steeghs; Maja J de Jonge; Marlies H G Langenberg; Lodewyk F A Wessels; Edwin P J G Cuppen; J H Schellens; Stefan Sleijfer; Martijn P Lolkema; Emile E Voest
Journal:  Oncotarget       Date:  2017-03-08

Review 8.  Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.

Authors:  Jean Christopher Chamcheu; Tithi Roy; Mohammad Burhan Uddin; Sergette Banang-Mbeumi; Roxane-Cherille N Chamcheu; Anthony L Walker; Yong-Yu Liu; Shile Huang
Journal:  Cells       Date:  2019-07-31       Impact factor: 6.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.